David Risinger
Stock Analyst at Leerink Partners
(4.52)
# 172
Out of 4,814 analysts
168
Total ratings
65.17%
Success rate
12.83%
Average return
Main Sectors:
Stocks Rated by David Risinger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $762 → $834 | $563.16 | +48.09% | 8 | Feb 5, 2025 | |
| JNJ Johnson & Johnson | Maintains: Outperform | $182 → $169 | $157.44 | +7.34% | 3 | Jan 23, 2025 | |
| ABBV AbbVie | Upgrades: Outperform | $206 | $173.00 | +19.08% | 7 | Nov 22, 2024 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Outperform | $55 → $73 | $49.23 | +48.30% | 4 | Nov 12, 2024 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $49 → $69 | $16.96 | +306.84% | 2 | Nov 11, 2024 | |
| TENX Tenax Therapeutics | Initiates: Outperform | $16 | $5.20 | +207.69% | 1 | Oct 24, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Outperform | $44 | $9.20 | +378.26% | 2 | Sep 17, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $106 → $153 | $30.50 | +401.64% | 2 | Sep 3, 2024 | |
| TBPH Theravance Biopharma | Downgrades: Market Perform | $15 → $10 | $8.62 | +16.01% | 3 | Aug 6, 2024 | |
| HLVX HilleVax | Downgrades: Market Perform | $28 → $2 | $1.69 | +18.34% | 2 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $47 | $20.58 | +128.38% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $267 → $318 | $277.29 | +14.68% | 4 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $11 | $12.25 | -10.20% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $410 → $458 | $839.90 | -45.47% | 16 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $42 | $58.66 | -28.40% | 3 | Mar 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $374 → $365 | $489.10 | -25.37% | 3 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $81 → $91 | $104.53 | -12.94% | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $49 → $48 | $22.15 | +116.75% | 14 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $10.14 | -1.38% | 4 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $10 | $29.10 | -65.64% | 2 | Jun 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $11.12 | +232.73% | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $162 → $176 | $102.02 | +72.52% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $16 | $7.39 | +116.51% | 1 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $53 → $45 | $25.37 | +77.37% | 17 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $22 → $35 | $4.60 | +661.70% | 4 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $41 | $8.44 | +385.78% | 5 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $167 → $174 | $148.66 | +17.05% | 9 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $51 | $32.51 | +56.87% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $8 | $13.64 | -41.33% | 19 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $97 → $89 | $77.98 | +14.13% | 8 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $7.36 | -59.24% | 4 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $16 | $27.05 | -40.85% | 9 | Apr 2, 2020 |
Regeneron Pharmaceuticals
Feb 5, 2025
Upgrades: Outperform
Price Target: $762 → $834
Current: $563.16
Upside: +48.09%
Johnson & Johnson
Jan 23, 2025
Maintains: Outperform
Price Target: $182 → $169
Current: $157.44
Upside: +7.34%
AbbVie
Nov 22, 2024
Upgrades: Outperform
Price Target: $206
Current: $173.00
Upside: +19.08%
Bristol-Myers Squibb Company
Nov 12, 2024
Upgrades: Outperform
Price Target: $55 → $73
Current: $49.23
Upside: +48.30%
Tectonic Therapeutic
Nov 11, 2024
Maintains: Outperform
Price Target: $49 → $69
Current: $16.96
Upside: +306.84%
Tenax Therapeutics
Oct 24, 2024
Initiates: Outperform
Price Target: $16
Current: $5.20
Upside: +207.69%
Oruka Therapeutics
Sep 17, 2024
Initiates: Outperform
Price Target: $44
Current: $9.20
Upside: +378.26%
Vaxcyte
Sep 3, 2024
Maintains: Outperform
Price Target: $106 → $153
Current: $30.50
Upside: +401.64%
Theravance Biopharma
Aug 6, 2024
Downgrades: Market Perform
Price Target: $15 → $10
Current: $8.62
Upside: +16.01%
HilleVax
Jul 9, 2024
Downgrades: Market Perform
Price Target: $28 → $2
Current: $1.69
Upside: +18.34%
Apr 16, 2024
Initiates: Outperform
Price Target: $47
Current: $20.58
Upside: +128.38%
Oct 11, 2023
Upgrades: Outperform
Price Target: $267 → $318
Current: $277.29
Upside: +14.68%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $11
Current: $12.25
Upside: -10.20%
May 1, 2023
Maintains: Outperform
Price Target: $410 → $458
Current: $839.90
Upside: -45.47%
Mar 16, 2023
Downgrades: Market Perform
Price Target: $42
Current: $58.66
Upside: -28.40%
Feb 8, 2023
Maintains: Outperform
Price Target: $374 → $365
Current: $489.10
Upside: -25.37%
Feb 3, 2023
Maintains: Market Perform
Price Target: $81 → $91
Current: $104.53
Upside: -12.94%
Feb 1, 2023
Maintains: Market Perform
Price Target: $49 → $48
Current: $22.15
Upside: +116.75%
Dec 19, 2022
Maintains: Outperform
Price Target: $8 → $10
Current: $10.14
Upside: -1.38%
Jun 24, 2022
Maintains: Market Perform
Price Target: $7 → $10
Current: $29.10
Upside: -65.64%
Feb 22, 2022
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $11.12
Upside: +232.73%
Apr 1, 2021
Maintains: Equal-Weight
Price Target: $162 → $176
Current: $102.02
Upside: +72.52%
Mar 10, 2021
Maintains: Equal-Weight
Price Target: $18 → $16
Current: $7.39
Upside: +116.51%
Mar 5, 2021
Maintains: Equal-Weight
Price Target: $53 → $45
Current: $25.37
Upside: +77.37%
Feb 26, 2021
Maintains: Equal-Weight
Price Target: $22 → $35
Current: $4.60
Upside: +661.70%
Nov 24, 2020
Maintains: Overweight
Price Target: $31 → $41
Current: $8.44
Upside: +385.78%
Nov 13, 2020
Maintains: Equal-Weight
Price Target: $167 → $174
Current: $148.66
Upside: +17.05%
Jul 13, 2020
Initiates: Equal-Weight
Price Target: $51
Current: $32.51
Upside: +56.87%
Apr 2, 2020
Maintains: Underweight
Price Target: $13 → $8
Current: $13.64
Upside: -41.33%
Apr 2, 2020
Maintains: Overweight
Price Target: $97 → $89
Current: $77.98
Upside: +14.13%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $7.36
Upside: -59.24%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $20 → $16
Current: $27.05
Upside: -40.85%